Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.01 (overall 0.09) | 0.01 |
| cell type Human Protein Atlas | cell type enhanced in other brain neurons (46 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 84 Parkinson's papers of 269 | 0.42 |
| pathways Reactome | 14 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 3101
Sealed predictions
- DCTN1 in dopamine neurons, braak-0.19 (p 0.618) → -0.45 (p 0.227)receipt 3110
Swarm cases
receipt 3110: DCTN1 in dopamine neurons, braak
- power
- full sample -0.33 (p 0.185, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.37 (p 0.132, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.38 (p 0.118, n 18). could be the mix.
- skeptic
- leave-one-out range -0.46 to -0.25, sign flips 0; without severely affected donors -0.33 (p 0.185, n 18). fragile.
- cell type
- strongest in oligodendrocytes: -0.66 (p 0.0030, n 18) vs -0.33 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DCTN1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up DCTN1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.30 p 0.286 (needs p < 6.2e-4)
Receipts
loading the receipts